Dr. Romm is currently a senior executive at Takeda Oncology leading medical affairs. She started her Pharmaceutical Industry career in 1997 at Roche. Since then, she moved to clinical research and helped to conduct Phase III/IV studies and IITs. She held multiple positions in Medical Affairs, including US Medical Director for European Biotech firms (Octapharma, BPL/DCI Biologics), field Medical positions at Global Pharma Companies (Novartis, Roche), small biotechs (Ipsen), and mid-size firms (Solvay, Allergan, Takeda). Julia developed Medical Affairs/ Med Communication strategy for US launches of several products in Hematology/ Oncology: IVIG in ITP, Proteasome Inhibitors in Multiple myeloma, TKI in CML/ALL, targeted therapy in AML, moAb in GVHD prophylaxis.
Julia has extensive experience collaborating with Academic Institutions/ Hematology/Oncology KOL relationships in the NorthEast and West spanning 20+ years. She collaborates with BD, R&D, Clinical Development, Value/Access, Marketing, Sales and is a molecule lead for I/O pipeline.
Julia Romm received a Ph.D. in Public Health at the Institute of Public Health of the Russian Federation, in Moscow, Russia. Julia holds a BSN (CA State University) with an emphasis in Public Health and holds a PH Certificate as well as OCN Certificate. She practiced Nursing at UCLA Medical Center. She also holds an MBA from Pepperdine University. Julia is ASCO, AACR, and ASH member.